R&D The diagnostic odyssey: Challenges and opportunities in tran... Transthyretin amyloidosis (ATTR) is a rarely diagnosed and relentless disease that demands our attention.
R&D When costing and compliance collide Only a few years ago, compliance was the undisputed top priority in the pharmaceutical industry - regardless of cost.
R&D Precision, speed, impact: Evolving mass spectrometry for med... MOBILion's Melissa Sherman explores the evolving role of mass spectrometry in drug discovery, complex molecule analysis, and medical research.
R&D Looking to early-stage companies for innovation, with Juerge... In an interview at BIO 2025, Bayer's Juergen Eckhardt discusses the importance of external innovation and why his company is prioritising early stage.
R&D Going wide on immune system activation, with Jeffrey Meckler Indaptus CEO Jeff Meckler discusses his company's unconventional approach to immunotherapy, based on activating a wide swath of the immune system.
Oncology ASCO 2026: Pluvicto shows consistency, with Dr Fred Saad In a conversation at ASCO 2026, Dr Fred Saad of the University of Montreal shared some insights from a subgroup analysis of Pluvicto
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
